M.D. Sass Concentrated Value UCITS Fund Surpasses $120 Million in Assets Following July Launch

NEW YORK — M.D. Sass, LLC launched the M.D. Sass Concentrated Value Fund (ISIN: IE000GK9WV20 – Bloomberg: MSCVEIU: ID) on 1 July 2026 with institutional capital from endowments, family offices and wealth managers in Europe and the UK.

The Fund provides European and UK investors access to M.D. Sass’s high-conviction US value equity strategy, which has grown to more than $2.5 billion in assets under management since its inception in 2019. The strategy is backed by a diversified investor base that includes US institutions, high net worth investors and a major Asian public pension fund.

The strategy follows a bottom-up, fundamental investment approach focused primarily on large- and mid-capitalisation US companies. The investment team seeks businesses where it has a differentiated view of future earnings relative to consensus. Its in-depth research focuses on companies at an inflection point, where changes in industry dynamics, operational improvements or company-specific catalysts can drive better-than-expected results and attractive incremental returns on invested capital. The strategy generally holds approximately 25 companies, allowing the team to concentrate its research on its highest-conviction ideas.

“We are pleased to make Concentrated Value available to investors across Europe and the UK,” said Ari Sass, President of M.D. Sass and Portfolio Manager of Concentrated Value. “Unlike many value-oriented managers, we believe valuation is an observation, not a thesis. We take an earnings-centric approach to investing, seeking opportunities where our earnings expectations are above consensus. Valuation informs margin of safety and risk/reward, but it does not drive idea generation. A differentiated view of the business does.

“Concentration allows us to devote significant resources to understanding the companies we own and developing conviction in our investment theses. But that conviction must always be balanced by intellectual honesty and a willingness to act when the facts change or new information invalidates our prior view. That balance has been central to how we have managed the strategy since inception.”

The Fund seeks long-term capital appreciation and is managed with reference to the Russell 1000 Value Total Return Index over a full market cycle. It is classified as an Article 8 fund under the EU Sustainable Finance Disclosure Regulation, incorporating negative screening and ESG considerations alongside the team’s fundamental research. The Fund is domiciled in Ireland and is available through a range of GBP, EUR and USD share classes in both hedged and unhedged form.

The Fund is a sub-fund of Strategic Investment Funds UCITS plc, an Irish-domiciled UCITS platform operated by Strategic Investments Group (“SIG”). SIG is a UK-based firm authorised and regulated by the Financial Conduct Authority and has provided investors access to alternative and long-only strategies through UCITS funds since 2010. SIG serves as platform coordinator and distributor for the Fund, supporting access for investors across the UK and Europe through its established European network.

About M.D. Sass

M.D. Sass, LLC is an independent boutique asset management firm founded in New York in 1972. For more than 50 years, the firm has developed differentiated investment strategies across a range of asset classes and market cycles, both managing portfolios directly and partnering with investment teams to build new investment businesses.

M.D. Sass is registered with the US Securities and Exchange Commission. Its clients include Fortune 500 companies, public pension plans, endowments and foundations, Taft-Hartley funds, family offices and high net worth individuals. As of 30 June 2026, M.D. Sass managed approximately $3 billion in assets.

Media contact

M.D. Sass Concentrated Value Strategy

SIG Investor Relations

Team Tel: +44 207 661 8154

Email: mdsass@sig-global.com

www sig-global.com

Important information

This is a marketing communication. It is intended for professional investors only and does not constitute investment advice or an offer or solicitation to buy or sell any investment. Please read the Prospectus, the Supplement and the Key Investor Document before making any investment decision. The value of investments and any income from them can fall as well as rise, and investors may not get back the amount originally invested. Past performance does not predict future returns. For share classes denominated in a currency other than the Fund’s US dollar base currency, returns may increase or decrease as a result of currency fluctuations.

Prospectus/Supplement/Key Investor Information:

A copy of the English version of the prospectus and supplement of the Fund and the Key Investor Information Document (KIID) relating to the Fund may be obtained online from SIG – md-sass-concentrated-value or alternatively received via email upon request by contacting info@sig-global.com or calling +44 (0) 207 661 8154. Where required under national rules, the KIID will also be available in the local language of the relevant EEA Member State.

Hyperlink to Summary of Investor Rights:

A summary of investor rights associated with an investment in the Fund is available online in English a Disclosures | FundRock Ireland or it may be received upon request via email by contacting info@sig-global.com

Termination of marketing arrangements:

A decision may be taken at any time to terminate the arrangements made for the marketing of the Fund in any EEA Member State in which it is currently marketed. In such circumstances, Shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the Fund free of any charges or deductions for at least 30 working days from the date of such notification.

Fund Information

Fund name: M.D. Sass Concentrated Value Fund. Legal Umbrella: Strategic Investment Funds UCITS Plc. Domicile: Ireland. Base currency: USD. Fund launch date: 1st July 2026. Management Company: FundRock Management Company (Ireland) Limited. Investment Manager: M.D. Sass, LLC. Depositary: State Street Fund Services (Ireland) Limited. Administrator: State Street Fund Services (Ireland) Limited. Dealing frequency and subscription and redemption notice periods are set out in the fund supplement.

Reference Index

The Russell 1000 Value is used for performance comparison only. The fund is actively managed and does not track or aim to replicate the index. The Russell 1000 Value is a market-capitalisation-weighted index measuring the large-cap value segment of the U.S. equity market. It is unmanaged and cannot be invested in directly.

Risk and Distribution

The shares of the Fund shall be offered or advertised in Switzerland exclusively to qualified investors as defined by Article 10 of the Collective Investment Schemes Act, as amended from time to time (“CISA”) (“Qualified Investors”). The Fund has not been approved by the Swiss Financial Market Supervisory Authority (“FINMA”) for offering in Switzerland to non-qualified investors.

This document is for discussion purposes only; it is not an offer or a solicitation to subscribe to the Fund or an offer to buy any securities in any jurisdiction, is not investment advice and it does not create any legally binding obligation on the part of M.D. Sass, SIG, or any other party. Sales of shares will be made on the basis of the prospectus and any supplements thereto only and cannot be offered in any jurisdiction in which such offer is not authorised. Investment in the Fund may not be suitable for all investors; investors should consider risks and other information in the prospectus and supplements and consult their professional advisers regarding suitability, legal, tax and economic consequences of an investment. Before making an investment in the Fund, investors should take steps to ensure that they fully understand the investment risks associated with the Fund and have made an independent assessment of the appropriateness of an investment in the Fund in light of their own objectives and circumstances. M.D. Sass, SIG, or any other party is not acting as your financial adviser or in any other fiduciary capacity in respect to this proposed transaction. The information contained in this document is based on material M.D. Sass and SIG believes to be reliable. The information contained in this document is not complete and is subject to updating, completion, modification and amendment. Assumptions, estimates, and opinions contained in this document are subject to change without notice.

The Strategic Investment Funds UCITS plc is an umbrella fund with segregated liability between sub-funds, established as an open-ended investment company with variable capital and incorporated with limited liability under the laws of Ireland. It has not been registered by the Financial Conduct Authority in the UK as a section 264 scheme. It will therefore be an unregulated collective investment scheme for the purposes of the UK Financial Services and Markets Act 2000 (FSMA). The distribution of this document in the UK is intended for Investment Professionals only. This document and the information contained herein may only be distributed, by an Authorised Person, within the UK to persons who are professional clients or eligible counterparties as set out in the FCA rules. The Fund is not available for public distribution. Any person with questions relating to their ability to invest in the Fund should consult a Financial Advisor. As the Fund is not regulated by the Financial Conduct Authority of the United Kingdom, investors may not have the benefit of the Financial Services Compensation Scheme and other protections afforded by the FCA or any of the rules and regulations made thereunder. The value of investments and the income from them can go down as well as up and investors may not get back the amounts originally invested. The Fund will be offered solely to non-US investors under the terms and conditions of the relevant prospectus and supplements. Opinions expressed above are subject to change without notice and do not take into account the particular investment objectives, financial situation or needs of individual investors. M.D. Sass,  SIG, and Strategic Investment Funds UCITS plc disclaim all liability for any direct, indirect, consequential or other losses or damages including loss of profits incurred by you or any third party that may arise from any reliance on this document or for the reliability or accuracy, completeness or timeliness thereof.